JP2020522695A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522695A5 JP2020522695A5 JP2019566313A JP2019566313A JP2020522695A5 JP 2020522695 A5 JP2020522695 A5 JP 2020522695A5 JP 2019566313 A JP2019566313 A JP 2019566313A JP 2019566313 A JP2019566313 A JP 2019566313A JP 2020522695 A5 JP2020522695 A5 JP 2020522695A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- subject
- myeloid
- neurotoxicity
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 153
- 238000000034 method Methods 0.000 claims description 125
- 206010029350 Neurotoxicity Diseases 0.000 claims description 100
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 100
- 231100000228 neurotoxicity Toxicity 0.000 claims description 100
- 230000007135 neurotoxicity Effects 0.000 claims description 100
- 238000002659 cell therapy Methods 0.000 claims description 86
- 238000011282 treatment Methods 0.000 claims description 61
- 210000000066 myeloid cell Anatomy 0.000 claims description 59
- 102000005962 receptors Human genes 0.000 claims description 54
- 108020003175 receptors Proteins 0.000 claims description 54
- 239000003550 marker Substances 0.000 claims description 45
- 239000003795 chemical substances by application Substances 0.000 claims description 38
- 239000000427 antigen Substances 0.000 claims description 37
- 108091007433 antigens Proteins 0.000 claims description 37
- 102000036639 antigens Human genes 0.000 claims description 37
- 238000002617 apheresis Methods 0.000 claims description 30
- 201000010099 disease Diseases 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 27
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 21
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 19
- 239000003153 chemical reaction reagent Substances 0.000 claims description 17
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 238000003556 assay Methods 0.000 claims description 15
- 230000018109 developmental process Effects 0.000 claims description 15
- 210000000265 leukocyte Anatomy 0.000 claims description 13
- 206010037660 Pyrexia Diseases 0.000 claims description 11
- 230000002829 reductive effect Effects 0.000 claims description 11
- 210000001616 monocyte Anatomy 0.000 claims description 9
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 8
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims description 8
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 210000005260 human cell Anatomy 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 231100000189 neurotoxic Toxicity 0.000 claims description 7
- 230000002887 neurotoxic effect Effects 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims description 6
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 6
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 6
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 6
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 6
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims description 6
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 6
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 claims description 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 6
- 108091008605 VEGF receptors Proteins 0.000 claims description 6
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000001605 fetal effect Effects 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 150000003431 steroids Chemical group 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 4
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 4
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims description 4
- 241000701022 Cytomegalovirus Species 0.000 claims description 4
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
- 102000010956 Glypican Human genes 0.000 claims description 4
- 108050001154 Glypican Proteins 0.000 claims description 4
- 108050007237 Glypican-3 Proteins 0.000 claims description 4
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims description 4
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims description 4
- -1 IFNγ Proteins 0.000 claims description 4
- 102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 claims description 4
- 108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 claims description 4
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims description 4
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims description 4
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 101800001271 Surface protein Proteins 0.000 claims description 4
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims description 4
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 4
- 208000008383 Wilms tumor Diseases 0.000 claims description 4
- 208000026448 Wilms tumor 1 Diseases 0.000 claims description 4
- 102100022748 Wilms tumor protein Human genes 0.000 claims description 4
- 101710127857 Wilms tumor protein Proteins 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 230000002238 attenuated effect Effects 0.000 claims description 4
- 108010039524 chondroitin sulfate proteoglycan 4 Proteins 0.000 claims description 4
- 230000008472 epithelial growth Effects 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 102000036215 folic acid binding proteins Human genes 0.000 claims description 4
- 108091011001 folic acid binding proteins Proteins 0.000 claims description 4
- 102000006495 integrins Human genes 0.000 claims description 4
- 108010044426 integrins Proteins 0.000 claims description 4
- 108010027445 interleukin-22 receptor Proteins 0.000 claims description 4
- 230000002025 microglial effect Effects 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 229960003323 siltuximab Drugs 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 229960003989 tocilizumab Drugs 0.000 claims description 4
- 239000002771 cell marker Substances 0.000 claims description 3
- 230000001934 delay Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 102000046699 human CD14 Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 230000001603 reducing effect Effects 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 3
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims description 2
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims description 2
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 206010048962 Brain oedema Diseases 0.000 claims description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 2
- 108700012439 CA9 Proteins 0.000 claims description 2
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims description 2
- 102100032912 CD44 antigen Human genes 0.000 claims description 2
- 108010058905 CD44v6 antigen Proteins 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims description 2
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 2
- 102000016736 Cyclin Human genes 0.000 claims description 2
- 108050006400 Cyclin Proteins 0.000 claims description 2
- 108010060273 Cyclin A2 Proteins 0.000 claims description 2
- 102100025191 Cyclin-A2 Human genes 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 101150029707 ERBB2 gene Proteins 0.000 claims description 2
- 102100038595 Estrogen receptor Human genes 0.000 claims description 2
- 108010087819 Fc receptors Proteins 0.000 claims description 2
- 102000009109 Fc receptors Human genes 0.000 claims description 2
- 101150032879 Fcrl5 gene Proteins 0.000 claims description 2
- 108091006027 G proteins Proteins 0.000 claims description 2
- 102000030782 GTP binding Human genes 0.000 claims description 2
- 108091000058 GTP-Binding Proteins 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 2
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 2
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 claims description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 2
- 101000796203 Homo sapiens L-dopachrome tautomerase Proteins 0.000 claims description 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 2
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 101000965721 Homo sapiens Volume-regulated anion channel subunit LRRC8A Proteins 0.000 claims description 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 2
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims description 2
- 102000000589 Interleukin-1 Human genes 0.000 claims description 2
- 108090000174 Interleukin-10 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102000004889 Interleukin-6 Human genes 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims description 2
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims description 2
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 claims description 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 claims description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 claims description 2
- 102100025096 Mesothelin Human genes 0.000 claims description 2
- 102100023123 Mucin-16 Human genes 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- 108060006580 PRAME Proteins 0.000 claims description 2
- 102000036673 PRAME Human genes 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 2
- 108010006700 Receptor Tyrosine Kinase-like Orphan Receptors Proteins 0.000 claims description 2
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 2
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 102100040985 Volume-regulated anion channel subunit LRRC8A Human genes 0.000 claims description 2
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 2
- 208000014619 adult acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 201000011184 adult acute lymphocytic leukemia Diseases 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 230000003432 anti-folate effect Effects 0.000 claims description 2
- 229940127074 antifolate Drugs 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- CXQCLLQQYTUUKJ-ALWAHNIESA-N beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->8)-alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp-(1<->1')-Cer(d18:1/18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@@H](CO)O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 CXQCLLQQYTUUKJ-ALWAHNIESA-N 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 208000006752 brain edema Diseases 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 102000003675 cytokine receptors Human genes 0.000 claims description 2
- 108010057085 cytokine receptors Proteins 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims description 2
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 claims description 2
- 108010051081 dopachrome isomerase Proteins 0.000 claims description 2
- 229950002507 elsilimomab Drugs 0.000 claims description 2
- 108010038795 estrogen receptors Proteins 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 239000004052 folic acid antagonist Substances 0.000 claims description 2
- 150000002270 gangliosides Chemical class 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 108040006870 interleukin-10 receptor activity proteins Proteins 0.000 claims description 2
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims description 2
- 102000009548 interleukin-22 receptor activity proteins Human genes 0.000 claims description 2
- 210000004901 leucine-rich repeat Anatomy 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 230000007774 longterm Effects 0.000 claims description 2
- 210000005087 mononuclear cell Anatomy 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 210000004986 primary T-cell Anatomy 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 102000003998 progesterone receptors Human genes 0.000 claims description 2
- 108090000468 progesterone receptors Proteins 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims description 2
- 229950006348 sarilumab Drugs 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 108010014402 tyrosinase-related protein-1 Proteins 0.000 claims description 2
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 8
- MYQAUKPBNJWPIE-UHFFFAOYSA-N 5-[[3-methoxy-4-[(4-methoxyphenyl)methoxy]phenyl]methyl]pyrimidine-2,4-diamine Chemical compound C1=CC(OC)=CC=C1COC(C(=C1)OC)=CC=C1CC1=CN=C(N)N=C1N MYQAUKPBNJWPIE-UHFFFAOYSA-N 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 3
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 3
- JGWRKYUXBBNENE-UHFFFAOYSA-N pexidartinib Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=C(Cl)C=C12 JGWRKYUXBBNENE-UHFFFAOYSA-N 0.000 description 3
- SHPFDGWALWEPGS-UHFFFAOYSA-N 1-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-methoxyphenyl]-3-[1-(1,3-thiazol-2-yl)ethyl]urea Chemical compound COC1=CC(OC=2C3=CC(OC)=C(OC)C=C3N=CC=2)=CC=C1NC(=O)NC(C)C1=NC=CS1 SHPFDGWALWEPGS-UHFFFAOYSA-N 0.000 description 2
- IBHNEKVLDKCEQY-UHFFFAOYSA-N 4-(2,4-difluoroanilino)-7-ethoxy-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide Chemical compound C=12C=C(N3CCN(C)CC3)C(OCC)=CC2=NC=C(C(N)=O)C=1NC1=CC=C(F)C=C1F IBHNEKVLDKCEQY-UHFFFAOYSA-N 0.000 description 2
- ADZBMFGQQWPHMJ-RHSMWYFYSA-N 4-[[2-[[(1r,2r)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C3SC(N[C@H]4[C@@H](CCCC4)O)=NC3=CC=2)=C1 ADZBMFGQQWPHMJ-RHSMWYFYSA-N 0.000 description 2
- NODCQQSEMCESEC-UHFFFAOYSA-N 5-(1h-pyrrolo[2,3-b]pyridin-3-ylmethyl)-n-[[4-(trifluoromethyl)phenyl]methyl]pyridin-2-amine Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=CC=C12 NODCQQSEMCESEC-UHFFFAOYSA-N 0.000 description 2
- BNVPFDRNGHMRJS-UHFFFAOYSA-N 5-cyano-n-[2-(4,4-dimethylcyclohexen-1-yl)-6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-yl]-1h-imidazole-2-carboxamide Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(N=2)C2CC(C)(C)OC(C)(C)C2)NC(=O)C=2NC=C(N=2)C#N)=C1 BNVPFDRNGHMRJS-UHFFFAOYSA-N 0.000 description 2
- GUBJNPWVIUFSTR-UHFFFAOYSA-N 5-cyano-n-[2-(cyclohexen-1-yl)-4-[1-[2-(dimethylamino)acetyl]piperidin-4-yl]phenyl]-1h-imidazole-2-carboxamide Chemical compound C1CN(C(=O)CN(C)C)CCC1C(C=C1C=2CCCCC=2)=CC=C1NC(=O)C1=NC(C#N)=CN1 GUBJNPWVIUFSTR-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010002998 NADPH Oxidases Proteins 0.000 description 2
- 102000004722 NADPH Oxidases Human genes 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- QYJOOVQLTTVTJY-YFKPBYRVSA-N ethyl (2s)-5-oxopyrrolidine-2-carboxylate Chemical compound CCOC(=O)[C@@H]1CCC(=O)N1 QYJOOVQLTTVTJY-YFKPBYRVSA-N 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- JUPOTOIJLKDAPF-UHFFFAOYSA-N n-[3-cyclopropyl-1-[(6-methylpyridin-2-yl)methyl]indazol-4-yl]-7-[2-(4-methylpiperazin-1-yl)ethoxy]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C1CN(C)CCN1CCOC1=CC2=NC=C(C(=O)NC=3C=4C(C5CC5)=NN(CC=5N=C(C)C=CC=5)C=4C=CC=3)N2C=C1 JUPOTOIJLKDAPF-UHFFFAOYSA-N 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- TVGAHWWPABTBCX-UHFFFAOYSA-N vimseltinib Chemical compound O=C1N(C)C(NC(C)C)=NC=C1C(N=C1C)=CC=C1OC1=CC=NC(C2=CN(C)N=C2)=C1 TVGAHWWPABTBCX-UHFFFAOYSA-N 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 108091033773 MiR-155 Proteins 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960002491 ibudilast Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023187446A JP2024016134A (ja) | 2017-06-02 | 2023-11-01 | 細胞療法に関連する毒性に関する製造物品および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762514762P | 2017-06-02 | 2017-06-02 | |
| US62/514,762 | 2017-06-02 | ||
| US201762515526P | 2017-06-05 | 2017-06-05 | |
| US62/515,526 | 2017-06-05 | ||
| PCT/US2018/035752 WO2018223098A1 (en) | 2017-06-02 | 2018-06-01 | Articles of manufacture and methods related to toxicity associated with cell therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023187446A Division JP2024016134A (ja) | 2017-06-02 | 2023-11-01 | 細胞療法に関連する毒性に関する製造物品および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020522695A JP2020522695A (ja) | 2020-07-30 |
| JP2020522695A5 true JP2020522695A5 (OSRAM) | 2021-07-26 |
| JP7379164B2 JP7379164B2 (ja) | 2023-11-14 |
Family
ID=62705743
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566313A Active JP7379164B2 (ja) | 2017-06-02 | 2018-06-01 | 細胞療法に関連する毒性に関する製造物品および方法 |
| JP2023187446A Pending JP2024016134A (ja) | 2017-06-02 | 2023-11-01 | 細胞療法に関連する毒性に関する製造物品および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023187446A Pending JP2024016134A (ja) | 2017-06-02 | 2023-11-01 | 細胞療法に関連する毒性に関する製造物品および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11740231B2 (OSRAM) |
| EP (1) | EP3631468A1 (OSRAM) |
| JP (2) | JP7379164B2 (OSRAM) |
| CN (1) | CN111201438A (OSRAM) |
| AU (1) | AU2018275891B2 (OSRAM) |
| CA (1) | CA3064597A1 (OSRAM) |
| MA (1) | MA48781A (OSRAM) |
| MX (1) | MX2019014288A (OSRAM) |
| WO (1) | WO2018223098A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| EP3716980A1 (en) * | 2017-12-01 | 2020-10-07 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
| EP4106775A4 (en) * | 2020-02-20 | 2024-03-06 | Kite Pharma, Inc. | CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY |
| WO2022016150A1 (en) * | 2020-07-17 | 2022-01-20 | Ross Peter M | Methods for the treatment of cytokine release syndromes |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2117571C3 (de) | 1971-04-10 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel |
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| IN165717B (OSRAM) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| WO1990007380A2 (en) | 1988-12-28 | 1990-07-12 | Stefan Miltenyi | Methods and materials for high gradient magnetic separation of biological materials |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| ATE159548T1 (de) | 1990-11-13 | 1997-11-15 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
| FR2688138B1 (fr) | 1992-03-06 | 1995-05-05 | Rhone Poulenc Rorer Sa | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique. |
| DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
| EP0672144A1 (en) | 1992-10-20 | 1995-09-20 | Chiron Corporation | Interleukin-6 receptor antagonists |
| EP0804590A1 (en) | 1993-05-21 | 1997-11-05 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| WO1996013593A2 (en) | 1994-10-26 | 1996-05-09 | Procept, Inc. | Soluble single chain t cell receptors |
| WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| US20020150914A1 (en) | 1995-06-30 | 2002-10-17 | Kobenhavns Universitet | Recombinant antibodies from a phage display library, directed against a peptide-MHC complex |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| US6451995B1 (en) | 1996-03-20 | 2002-09-17 | Sloan-Kettering Institute For Cancer Research | Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods |
| CA2305630C (en) | 1997-10-02 | 2012-11-06 | Sunol Molecular Corporation | Soluble single-chain t-cell receptor proteins |
| ES2168866T3 (es) | 1998-05-19 | 2002-06-16 | Avidex Ltd | Receptor de celulas t soluble. |
| EP1109921A4 (en) | 1998-09-04 | 2002-08-28 | Sloan Kettering Inst Cancer | FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF |
| US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| AU2001265346A1 (en) | 2000-06-02 | 2001-12-17 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| US7446179B2 (en) | 2000-11-07 | 2008-11-04 | City Of Hope | CD19-specific chimeric T cell receptor |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| ATE290020T1 (de) | 2001-08-31 | 2005-03-15 | Avidex Ltd | Löslicher t zell rezeptor |
| US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| EP1485075A4 (en) | 2002-02-20 | 2006-04-26 | Dyax Corp | MHC-PEPTIDE COMPLEX BINDING LIGANDS |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| EP3020414B1 (en) | 2002-09-06 | 2018-10-24 | Amgen Inc. | Therapeutic anti-il-1r1 monoclonal antibody |
| NZ539225A (en) | 2002-10-09 | 2006-09-29 | Avidex Ltd | Single chain recombinant T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US20090226474A1 (en) | 2004-05-27 | 2009-09-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| US20090304679A1 (en) | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| AU2005247950B2 (en) | 2004-05-27 | 2012-02-02 | Receptor Logic, Inc. | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| AU2005265017A1 (en) | 2004-06-17 | 2006-01-26 | Plexxikon, Inc. | Azaindoles modulating c-kit activity and uses therefor |
| DK1791865T3 (da) | 2004-06-29 | 2010-11-01 | Immunocore Ltd | Celler der udtrykker en modificeret T-cellerecptor |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| US7645755B2 (en) | 2004-10-22 | 2010-01-12 | Janssen Pharmaceutical N.V. | Inhibitors of c-fms kinase |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| ES2673973T3 (es) | 2006-09-22 | 2018-06-26 | Pharmacyclics Llc | Inhibidores de tirosina cinasa de Bruton |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| WO2008097596A2 (en) | 2007-02-08 | 2008-08-14 | Biogen Idec Ma Inc. | Nrf2 screening assays and related methods and compositions |
| WO2008121420A1 (en) | 2007-03-30 | 2008-10-09 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
| US8747290B2 (en) | 2007-12-07 | 2014-06-10 | Miltenyi Biotec Gmbh | Centrifuge for separating a sample into at least two components |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| CA2712000A1 (en) | 2008-01-28 | 2009-08-06 | Medimmune Limited | Stabilized angiopoietin-2 antibodies and uses thereof |
| WO2009099553A2 (en) | 2008-02-01 | 2009-08-13 | The Regents Of The University Of California | Use of kinase inhibitor in treatment of atherosclerosis |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| JP2012503017A (ja) | 2008-09-19 | 2012-02-02 | パラテック ファーマシューティカルズ インコーポレイテッド | 関節リウマチの治療用のテトラサイクリン化合物および関連する治療方法 |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| AU2010276324A1 (en) | 2009-07-20 | 2012-02-02 | The Regents Of The University Of California | Phenotyping tumor-infiltrating leukocytes |
| WO2011044186A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| SI2496698T1 (sl) | 2009-11-03 | 2019-07-31 | City Of Hope | Skrajšan epiderimalni receptor faktorja rasti (EGFRt) za selekcijo transduciranih T celic |
| KR101580714B1 (ko) | 2010-06-03 | 2016-01-04 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| SG193591A1 (en) | 2011-03-23 | 2013-10-30 | Hutchinson Fred Cancer Res | Method and compositions for cellular immunotherapy |
| EP3323833B1 (en) | 2011-04-01 | 2019-12-04 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like bispecific antibodies specific for a wt1 peptide presented by hla-a2 |
| PT2704713T (pt) | 2011-05-05 | 2017-04-24 | Novartis Ag | Inibidores de csf-1r para tratamento de tumores cerebrais |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| MX359234B (es) | 2011-11-11 | 2018-09-20 | Hutchinson Fred Cancer Res | Inmunoterapia de celulas t objetivadas en ciclina a1 para cancer. |
| ES2774160T3 (es) | 2012-02-13 | 2020-07-17 | Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute | Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| US20150119267A1 (en) | 2012-04-16 | 2015-04-30 | Sloan-Kettering Institute For Cancer Research | Inhibition of colony stimulating factor-1 receptor signaling for the treatment of brain cancer |
| BR112014027374B1 (pt) | 2012-05-03 | 2022-05-31 | Fred Hutchinson Cancer Research Center | Método para gerar um receptor de células t (tcr) com afinidade aumentada |
| KR20150015021A (ko) | 2012-06-04 | 2015-02-09 | 파마시클릭스, 인코포레이티드 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
| GB201211310D0 (en) | 2012-06-26 | 2012-08-08 | Chroma Therapeutics Ltd | CSF-1R kinase inhibitors |
| RS61345B1 (sr) | 2012-08-20 | 2021-02-26 | Hutchinson Fred Cancer Res | Postupak i kompozicije za ćelijsku imunoterapiju |
| CN104853766A (zh) | 2012-10-02 | 2015-08-19 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| CN104781789B (zh) | 2012-12-20 | 2018-06-05 | 三菱电机株式会社 | 车载装置 |
| US20140227219A1 (en) * | 2013-02-08 | 2014-08-14 | University Of Central Florida Research Foundation, Inc. | Compositions and Methods Comprising BMP-7 |
| US10017741B2 (en) | 2013-03-15 | 2018-07-10 | Stemcell Technologies Inc. | Compositions and methods for obtaining enriched mesenchymal stem cell cultures |
| SG11201507688VA (en) | 2013-03-15 | 2015-10-29 | Sloan Kettering Inst Cancer | Compositions and methods for immunotherapy |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| PL4368705T3 (pl) | 2014-03-11 | 2025-05-19 | Cellectis | Sposób wytwarzania limfocytów t kompatybilnych do przeszczepienia allogenicznego |
| CN114107424A (zh) | 2014-10-08 | 2022-03-01 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
| EP3932950A1 (en) | 2014-10-20 | 2022-01-05 | Juno Therapeutics, Inc. | Methods and compositions for dosing in adoptive cell therapy |
| CN116334205A (zh) | 2015-09-03 | 2023-06-27 | 诺华股份有限公司 | 预测细胞因子释放综合征的生物标志物 |
| BR112019017767A2 (pt) * | 2017-02-27 | 2020-04-07 | Juno Therapeutics Inc | composições, artigos de fabricação e métodos relacionados à dosagem em terapia celular |
-
2018
- 2018-06-01 EP EP18733465.1A patent/EP3631468A1/en active Pending
- 2018-06-01 MA MA048781A patent/MA48781A/fr unknown
- 2018-06-01 US US16/617,477 patent/US11740231B2/en active Active
- 2018-06-01 MX MX2019014288A patent/MX2019014288A/es unknown
- 2018-06-01 WO PCT/US2018/035752 patent/WO2018223098A1/en not_active Ceased
- 2018-06-01 CA CA3064597A patent/CA3064597A1/en active Pending
- 2018-06-01 AU AU2018275891A patent/AU2018275891B2/en not_active Expired - Fee Related
- 2018-06-01 CN CN201880050034.8A patent/CN111201438A/zh active Pending
- 2018-06-01 JP JP2019566313A patent/JP7379164B2/ja active Active
-
2023
- 2023-07-05 US US18/347,434 patent/US20240151713A1/en active Pending
- 2023-11-01 JP JP2023187446A patent/JP2024016134A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cai et al. | Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy | |
| Marin-Acevedo et al. | Next generation of immune checkpoint inhibitors and beyond | |
| Marin-Acevedo et al. | Next generation of immune checkpoint therapy in cancer: new developments and challenges | |
| JP7034125B2 (ja) | Ｃａｒの抗腫瘍活性のための毒性管理 | |
| JP2020522489A5 (OSRAM) | ||
| Kim et al. | Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas | |
| Lee et al. | Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity | |
| JP2022514262A (ja) | 双子型免疫細胞エンゲージャー | |
| Kaesler et al. | Targeting tumor-resident mast cells for effective anti-melanoma immune responses | |
| JP2021508317A5 (OSRAM) | ||
| JP2020522695A5 (OSRAM) | ||
| US20190358262A1 (en) | Methods for modulation of car-t cells | |
| Ritchie et al. | Mechanisms of action and clinical development of elotuzumab | |
| Sims et al. | Biomarkers for glioma immunotherapy: the next generation | |
| Huang et al. | Use of a universal targeting CAR T cell to simultaneously kill cancer cells and cancer-associated fibroblasts | |
| JP2022515187A (ja) | 癌の治療における放射免疫療法と免疫チェックポイント療法との組み合わせ | |
| Moreno Ayala et al. | Immunotherapy for the treatment of breast cancer | |
| CN111201438A (zh) | 与和细胞疗法相关的毒性有关的制品和方法 | |
| Cadilha et al. | Enabling T cell recruitment to tumours as a strategy for improving adoptive T cell therapy | |
| JP2022524994A (ja) | Ｔ細胞受容体及びその使用方法 | |
| JP2022523554A (ja) | Ｔ細胞受容体及びその使用方法 | |
| JP2022524993A (ja) | Ｔ細胞受容体及びその使用方法 | |
| Ibrahim et al. | Naive CD4+ T cells carrying a TLR2 agonist overcome TGF-β–mediated tumor immune evasion | |
| JP2022523971A (ja) | Ｔ細胞受容体及びその使用方法 | |
| JPWO2020252218A5 (OSRAM) |